诺华地拉罗司最新价格

The latest price from Novartis: Asunra, deferasirox produced by Novartis in Switzerland, is 400mg*30 tablets and costs about $420 per box.

Deferasirox is currently the only oral iron chelator developed by Novartis. Novartis AG of Switzerland is a leading multinational company in the global pharmaceutical and consumer healthcare industries. Novartis focuses on the growth areas of pharmaceuticals and healthcare and has a diversified business portfolio of innovative drugs, preventive vaccines and diagnostic reagents, as well as consumer healthcare products to best meet the needs of patients and society.

Deferasirox dispersible tablets are mainly suitable for patients with iron accumulation due to long-term blood transfusion (such as thalassemia or other rare anemias). It is suitable for children over two years old and adults. Enriga should not be used with other iron chelation treatments as the safety of such combined use has not been established.

Recommended for patients with iron accumulation, such as those who require long-term blood transfusion (blood transfusion volume up to 100 ml/kg) and serum ferritin exceeds 1000 μg/L; corresponding to body weight, it is initially recommended to take a daily dose of 20 mg/kg of deferasirox. Depending on the improvement of serum ferritin indicators, patients may need to adjust or increase the dose of deferasirox. Generally, the dose will be increased in units of 5 mg/kg or 10 mg/kg, but the total dose should not exceed 30 mg/kg per day.

The absolute bioavailability (AUC) of the tablets is 73.5±12.8%. After a single dose and under steady-state conditions, the Cmax and AUC of deferasirox increased approximately linearly with dose. After multiple doses, the exposure level of deferasirox increased, with an accumulation factor of 1.3-2.3. The absolute bioavailability (AUC) of deferasirox orally dispersible tablets is approximately 70% of intravenous administration.

Recommended related hot articles: /newsDetail/88617.html